Holen Sie sich die Stockscreener-App
18.35
2.60%
-0.49
Handel nachbörslich:
18.36
0.010
+0.05%
Schlusskurs vom Vortag:
$18.84
Offen:
$18.79
24-Stunden-Volumen:
1.31M
Relative Volume:
0.59
Marktkapitalisierung:
$3.03B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-446.21M
KGV:
-5.1786
EPS:
-3.5434
Netto-Cashflow:
$-423.92M
1W Leistung:
+7.37%
1M Leistung:
+23.49%
6M Leistung:
+45.06%
1J Leistung:
+121.62%
1-Tages-Spanne:
$18.32
$19.05
1-Wochen-Bereich:
$17.45
$19.05
52-Wochen-Spanne:
$6.36
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.35 | 3.11B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Targets Report: Is now the right time to enter Dyne Therapeutics Inc2026 Sector Review & Momentum Based Trading Ideas - baoquankhu1.vn
Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tax-driven share sale by Dyne (DYN) CFO Lucera Erick disclosed - Stock Titan
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders - Sahm
Dyne Therapeutics, Inc. (DYN) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - Sahm
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) adds 2,000 common shares - Stock Titan
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Fed Watch: Can Dyne Therapeutics Inc disrupt its industryMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DYN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Technical Reactions to DYN Trends in Macro Strategies - Stock Traders Daily
Is Dyne Therapeutics Inc a turnaround storyPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4 - Insider Monkey
Vanguard disaggregates holdings; Dyne Therapeutics (NASDAQ: DYN) shows 0 ownership - stocktitan.net
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
Raymond James reiterates Strong Buy on Dyne Therapeutics stock By Investing.com - Investing.com Canada
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co. - MarketBeat
Dyne Therapeutics (DYN) shares key details for pivotal drugs - MSN
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval - Muscular Dystrophy News
Dyne Therapeutics (NASDAQ:DYN) Trading 4.4% HigherHere's Why - MarketBeat
Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel Conference - MarketBeat
Published on: 2026-03-19 20:58:12 - baoquankhu1.vn
Dyne Therapeutics details complex risk patterns and urgent care need for DM1 patients - Traders Union
Retail Trends: Is now the right time to enter Dyne Therapeutics IncOil Prices & Comprehensive Market Scan Insights - baoquankhu1.vn
Earnings Beat: Will Dyne Therapeutics Inc benefit from government policyWeekly Gains Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Trading the Move, Not the Narrative: (DYN) Edition - Stock Traders Daily
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart.com
MDA 2026: Dyne therapy boosts strength, cognition in DM1 - Muscular Dystrophy News
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN) - The Globe and Mail
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)? - simplywall.st
Why Dyne Therapeutics Stock Is Surging Higher Now - TipRanks
Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case - simplywall.st
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data - Yahoo Finance
Integral Health Asset Management LLC Buys New Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Insider Sold Shares Worth $2,530,562, According to a Recent SEC Filing - marketscreener.com
Director buys 2,000 Dyne Therapeutics (DYN) shares in open market - Stock Titan
Fund tied to Dyne Therapeutics (DYN) director sells stock - Stock Titan
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs - Insider Monkey
WINTON GROUP Ltd Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data - simplywall.st
5 Best Day Trading Stocks to Buy Now - Insider Monkey
Dyne Therapeutics launches phase 3 trial for DM1 treatment By Investing.com - Investing.com Nigeria
688K Dyne Therapeutics (DYN) shares sold by ForDyne fund under 10b5-1 plan - Stock Titan
ForDyne B.V. (DYN) reports two Common stock dispositions on consecutive dates - Stock Titan
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dyne Therapeutics Inc-Aktie (DYN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Posner Brian S | Director |
Mar 30 '26 |
Buy |
17.08 |
2,000 |
34,160 |
15,500 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):